 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 927822-86-4 |
| Molecular formula(MF) | C16H16Cl4N2O4S4 |
| Molecular Weight(MW): | 570.38 |
| Alias |
| In vitro | DMSO | 100 mg/mL (175.32 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL | |
| In vivo |
| Description | KC7F2 is a selective HIF-1α transcription inhibitor with IC50 of 20 μM in a cell-based assay. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
KC7F2 inhibits HRE-driven transcription and decreases HIF-1α protein levels in LN229-HRE-AP cells. KC7F2 shows a dose-response cytotoxicity with IC50 of approximately 15 to 25 μM in cancer cells MCF7, LNZ308, A549, U251MG, and LN229. In D54MG glioma cells, KC7F2 inhibits colony formation, especially under hypoxia. [1] In hypoxic microglial cultures, KC7F2 downregulates the expression of TfR and DMT, and reduces the HIF-1α mediated iron accumulation. [2] |
||
| In vivo | KC7F2 significantly reduces the latent period in the pentylenetetrazole kindling rat model and increases the rate of spontaneous recurrent seizures during the chronic stage in the lithium-pilocarpine rat model. [3] |